Quantitative rationalization of gemfibrozil drug interactions: Consideration of transporters-enzyme interplay and the role of circulating metabolite gemfibrozil 1-O-b-Glucuronide

Drug Metabolism and Disposition

Volumn 43, Issue 7, 2015, Pages 1108-1118

  Varma, Manthena V S ^a   Lin, Jian ^a   Bi, Yi An ^a   Kimoto, Emi ^a   Rodrigues, A David ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DRUG METABOLITE; EMPAGLIFLOZIN; EZETIMIBE; GEMFIBROZIL; GEMFIBROZIL 1 O BETA GLUCURONIDE; IBUPROFEN; IMATINIB; ITRACONAZOLE; LOPERAMIDE; PIOGLITAZONE; PRAVASTATIN; REPAGLINIDE; ROSIGLITAZONE; ROSUVASTATIN; SITAGLIPTIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; UNCLASSIFIED DRUG; ZOPICLONE; ANTILIPEMIC AGENT; CARRIER PROTEIN; CYTOCHROME P450 INHIBITOR; ENZYME; GLUCURONIDE; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 3; SLCO1B1 PROTEIN, HUMAN;

AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG INTERACTION; DRUG TRANSPORT; MATHEMATICAL MODEL; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; SIMULATION; ALGORITHM; BIOLOGICAL MODEL; COMPUTER SIMULATION; HUMAN; METABOLISM;

ALGORITHMS; AREA UNDER CURVE; CARRIER PROTEINS; COMPUTER SIMULATION; CYTOCHROME P-450 CYP2C8; CYTOCHROME P-450 ENZYME INHIBITORS; DRUG INTERACTIONS; ENZYMES; GEMFIBROZIL; GLUCURONIDES; HUMANS; HYPOLIPIDEMIC AGENTS; MODELS, BIOLOGICAL; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT;

EID: 84940384444     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.064303     Document Type: Article

References (93)

1. Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, and Kompella UB, et al. (2013) Impact of the CYP2C8 3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol 75:217-226.
2. Arun KP, Meda VS, Raj Kucherlapati VS, Dubala A, Deepalakshmi M, VijayaKumar PR, Elango K, and Suresh B (2012) Pharmacokinetic drug interaction between gemfibrozil and sitagliptin in healthy Indian male volunteers. Eur J Clin Pharmacol 68:709-714.
3. Backman JT, Honkalammi J, Neuvonen M, Kurkinen KJ, Tornio A, Niemi M, and Neuvonen PJ (2009) CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug Metab Dispos 37:2359-2366.
4. Backman JT, Kyrklund C, Kivistö KT, Wang JS, and Neuvonen PJ (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68:122-129.
5. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691.
6. Baldwin SJ, Clarke SE, and Chenery RJ (1999) Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 48: 424-432.
7. Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, Lin J, and Varma MV (2013) Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. Expert Opin Drug Metab Toxicol 9:459-472.
8. Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Brentano C, and Jaillon P (1999) Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos 27:1068-1073.
9. Bidstrup TB, Bjørnsdottir I, Sidelmann UG, Thomsen MS, and Hansen KT (2003) CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 56:305-314.
10. Callegari E, Kalgutkar AS, Leung L, Obach RS, Plowchalk DR, and Tse S (2013) Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development. Drug Metab Dispos 41:2047-2055.
11. Camenisch G and Umehara K (2012) Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drugdrug interactions. Biopharm Drug Dispos 33:179-194.
12. Center for Drug Evaluation and Research (CDER) (2012) Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations [Draft Guidance], U.S. Department of Health and Human Services, Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf.
13. Chang SY, Li W, Traeger SC, Wang B, Cui D, Zhang H, Wen B, and Rodrigues AD (2008) Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)-And (R)-(2 )-ibuprofen hydroxylation in vitro. Drug Metab Dispos 36:2513-2522.
14. Chen CH, Uang YS, Wang ST, Yang JC, and Lin CJ (2012) Interaction between red yeast rice and CYP450 enzymes/P-glycoprotein and its implication for the clinical pharmacokinetics of lovastatin. Evid Based Complement Alternat Med 2012:127043.
15. Chen Y, Mao J, and Hop CE (2015) Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone. Drug Metab Dispos 43:182-189.
16. Committee for Human Medicinal Products (CHMP) (2012) Guideline on the Investigation of Drug Interactions [Final], European Medicines Agency, London. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf.
17. Dekhuijzen PN and Koopmans PP (2002) Pharmacokinetic profile of zafirlukast. Clin Pharmacokinet 41:105-114.
18. Deng LJ,Wang F, and Li HD (2005) Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 61:831-836.
19. Fahmi OA, Maurer TS, Kish M, Cardenas E, Boldt S, and Nettleton D (2008) A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab Dispos 36:1698-1708.
20. Farmer JA (2001) Learning from the cerivastatin experience. Lancet 358:1383-1385.
21. Feng B, Hurst S, Lu Y, Varma MV, Rotter CJ, El-Kattan A, Lockwood P, and Corrigan B (2013) Quantitative prediction of renal transporter-mediated clinical drug-drug interactions. Mol Pharm 10:4207-4215.
22. Filppula AM, Tornio A, Niemi M, Neuvonen PJ, and Backman JT (2013) Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. Clin Pharmacol Ther 94:383-393.
23. Floyd JS, Kaspera R, Marciante KD, Weiss NS, Heckbert SR, Lumley T, Wiggins KL, Tamraz B, Kwok PY, and Totah RA, et al. (2012) A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel. Clin Pharmacol Ther 91:896-904.
24. Fujino H, Shimada S, Yamada I, Hirano M, Tsunenari Y, and Kojima J (2003) Studies on the interaction between fibrates and statins using human hepatic microsomes. Arzneimittelforschung 53:701-707.
25. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, Alton K, Patrick JE, and Zbaida S (2004) Identification of human UDP-glucuronosyltransferase enzyme( s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32: 314-320.
26. Honkalammi J, Niemi M, Neuvonen PJ, and Backman JT (2011a) Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab Dispos 39:1977-1986.
27. Honkalammi J, Niemi M, Neuvonen PJ, and Backman JT (2011b) Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. Clin Pharmacol Ther 89:579-586.
28. Honkalammi J, Niemi M, Neuvonen PJ, and Backman JT (2012) Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clin Pharmacol Ther 91:846-855.
29. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, and Hillgren KM, et al.; International Transporter Consortium (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9:215-236.
30. Isoherranen N, Hachad H, Yeung CK, and Levy RH (2009) Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. Chem Res Toxicol 22:294-298.
31. Jaakkola T, Backman JT, Neuvonen M, and Neuvonen PJ (2005) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin Pharmacol Ther 77:404-414.
32. Jaakkola T, Laitila J, Neuvonen PJ, and Backman JT (2006) Pioglitazone is metabolised YP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin Pharmacol Toxicol 99:44-51.
33. Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, and Rowland-Yeo K (2014) A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine. Clin Pharmacokinet 53:73-87.
34. Jenkins SM, Zvyaga T, Johnson SR, Hurley J, Wagner A, Burrell R, Turley W, Leet JE, Philip T, and Rodrigues AD (2011) Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-b-glucuronide of gemfibrozil. Drug Metab Dispos 39:2421-2430.
35. Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, and Galetin A, et al. (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007-1017.
36. Kajosaari LI, Laitila J, Neuvonen PJ, and Backman JT (2005a) Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin Pharmacol Toxicol 97:249-256.
37. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, and Backman JT (2005b) Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 78: 388-399.
38. Kalliokoski A, Backman JT, Kurkinen KJ, Neuvonen PJ, and Niemi M (2008) Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther 84:488-496.
39. Kaminsky LS and Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73: 67-74.
40. Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, and Backman JT (2010) Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther 88:223-230.
41. Karonen T, Neuvonen PJ, and Backman JT (2011) The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. Eur J Clin Pharmacol 67:151-155.
42. Karonen T, Neuvonen PJ, and Backman JT (2012) CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br J Clin Pharmacol 73:257-267.
43. Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, and Ueda K, et al. (2003) The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 18:365-372.
44. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDPglucuronosyltransferase cofactors in alamethicin-Activated human liver microsomes. Drug Metab Dispos 37:82-89.
45. Kim KA, Chung J, Jung DH, and Park JY (2004) Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur J Clin Pharmacol 60:575-581.
46. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, and Alton KB (2005) Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44:467-494.
47. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, and Neuvonen PJ (2001) Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 69:340-345.
48. Kyrklund C, Backman JT, Neuvonen M, and Neuvonen PJ (2003) Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 73: 538-544.
49. Lai XS, Yang LP, Li XT, Liu JP, Zhou ZW, and Zhou SF (2009) Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metab 10: 1009-1047.
50. Li R, Barton HA, and Varma MV (2014) Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved. Clin Pharmacokinet 53:659-678.
51. Lilja JJ, Backman JT, and Neuvonen PJ (2005) Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br J Clin Pharmacol 59:433-439.
52. Liu L and Pang KS (2005) The roles of transporters and enzymes in hepatic drug processing. Drug Metab Dispos 33:1-9.
53. Macha S, Koenen R, Sennewald R, Schöne K, Hummel N, Riedmaier S, Woerle HJ, Salsali A, and Broedl UC (2014) Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers. Clin Ther 36:280-290.e1.
54. Mück W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, and Kuhlmann J (1997) Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther 35:255-260.
55. Nakagomi-Hagihara R, Nakai D, and Tokui T (2007a) Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. Xenobiotica 37:416-426.
56. Nakagomi-Hagihara R, Nakai D, Tokui T, Abe T, and Ikeda T (2007b) Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica 37:474-486.
57. Nebot N, Crettol S, d'Esposito F, Tattam B, Hibbs DE, and Murray M (2010) Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 161:1059-1069.
58. Nicolas JM, Chanteux H, Rosa M, Watanabe S, and Stockis A (2012) Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos 40:1466-1472.
59. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, and Neuvonen PJ (2003a) Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46: 1319-1323.
60. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivistö KT, and Neuvonen PJ (2005) Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 77:468-478.
61. Niemi M, Backman JT, Neuvonen M, and Neuvonen PJ (2003b) Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46: 347-351.
62. Niemi M, Neuvonen PJ, and Kivistö KT (2001) Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 70:439-445.
63. Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, and Backman JT (2006) Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol 62:463-472.
64. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, and Tremaine LM (2006) The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
65. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, and Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197.
66. Oswald S, König J, Lütjohann D, Giessmann T, Kroemer HK, Rimmbach C, Rosskopf D, Fromm MF, and Siegmund W (2008) Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genomics 18:559-568.
67. Pang KS and Rowland M (1977) Hepatic clearance of drugs. II. Experimental evidence for acceptance of the "well-stirred" model over the "parallel tube" model using lidocaine in the perfused rat liver in situ preparation. J Pharmacokinet Biopharm 5:655-680.
68. Patiño-Rodríguez O, Torres-Roque I, Martínez-Delgado M, Escobedo-Moratilla A, and Pérez-Urizar J (2014) Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe. Front Pharmacol 5:261.
69. Prueksaritanont T, Ma B, and Yu N (2003) The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 56: 120-124.
70. Reyderman L, Kosoglou T, Statkevich P, Pember L, Boutros T, Maxwell SE, Affrime M, and Batra V (2004) Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Int J Clin Pharmacol Ther 42:512-518.
71. Rodgers T and Rowland M (2006) Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238-1257.
72. Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, and Isoherranen N (2014) Fluoxetine-And norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther 95:653-662.
73. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, and Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455-463.
74. Shitara Y, Hirano M, Sato H, and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
75. Shitara Y, Horie T, and Sugiyama Y (2006) Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 27:425-446.
76. Shitara Y and Sugiyama Y (2006) Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 112:71-105.
77. Spencer CM and Barradell LB (1996) Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs 51:982-1018.
78. Tornio A, Filppula AM, Kailari O, Neuvonen M, Nyrönen TH, Tapaninen T, Neuvonen PJ, Niemi M, and Backman JT (2014) Glucuronidation converts clopidogrel to a strong timedependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin Pharmacol Ther 96:498-507.
79. Tornio A, Neuvonen PJ, and Backman JT (2006) The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur J Clin Pharmacol 62:645-651.
80. Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ, and Backman JT (2008) The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther 84:403-411.
81. Tornio A, Niemi M, Neuvonen PJ, and Backman JT (2007) Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. Eur J Clin Pharmacol 63:463-469.
82. VandenBrink BM, Foti RS, Rock DA, Wienkers LC, and Wahlstrom JL (2011) Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab Dispos 39:1546-1554.
83. Varma MV, Bi YA, Kimoto E, and Lin J (2014) Quantitative prediction of transporter-And enzyme-mediated clinical drug-drug interactions of organic anion-transporting polypeptide 1B1 substrates using a mechanistic net-effect model. J Pharmacol Exp Ther 351:214-223.
84. Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, and Bergman A (2012) Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions. Pharm Res 29:2860-2873.
85. Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, and Kumar V (2013a) Mechanistic modeling to predict the transporter-And enzyme-mediated drug-drug interactions of repaglinide. Pharm Res 30:1188-1199.
86. Varma MV, Lin J, Bi YA, Rotter CJ, Fahmi OA, Lam JL, El-Kattan AF, Goosen TC, and Lai Y (2013b) Quantitative prediction of repaglinide-rifampicin complex drug interactions using dynamic and static mechanistic models: delineating differential CYP3A4 induction and OATP1B1 inhibition potential of rifampicin. Drug Metab Dispos 41:966-974.
87. Varma MV, Pang KS, Isoherranen N, and Zhao P (2015) Dealing with the complex drug-drug interactions: towards mechanistic models. Biopharm Drug Dispos 36:71-92.
88. Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, and Chen L, et al. (2007) Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 35:533-538.
89. Wang RW, Kari PH, Lu AY, Thomas PE, Guengerich FP, and Vyas KP (1991) Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 290:355-361.
90. Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, and Hartman D (2011) Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol 51:378-388.
91. Yeung CK, Fujioka Y, Hachad H, Levy RH, and Isoherranen N (2011) Are circulating metabolites important in drug-drug interactions Quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther 89:105-113.
92. Yu H, Balani SK, Chen W, Cui D, He L, Humphreys WG, Mao J, Lai WG, Lee AJ, and Lim HK, et al. (2015) Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the drug metabolism leadership group of the innovation and quality consortium metabolite group. Drug Metab Dispos 43:620-630.
93. Zamek-Gliszczynski MJ, Chu X, Polli JW, Paine MF, and Galetin A (2014) Understanding the transport properties of metabolites: case studies and considerations for drug development. Drug Metab Dispos 42:650-664.